Global Treatment-Resistant Depression Market – Industry Trends and Forecast to 2030

Treatment-Resistant Depression Market Analysis and Size

The rising incidence of treatment-resistant depression has caused consciousness associated with its treatment. Numerous market players are developing advanced drugs that can be administered through nasal and intravenous routes compared to the traditional oral route of administration. Morbidity and mortality globally resulting from psychiatric disorders predominantly by depression. Several advances in the treatment rate and increased adoption of a sedentary lifestyle are some of the major impacting factors for the demand for treatment-resistant depression drugs.

Data Bridge Market Research analyses a growth rate in treatment-resistant depression market in the forecast period 2023-2030. The expected CAGR of treatment-resistant depression market tend to be around 3.90% in the mentioned forecast period. The market was valued at USD 1180 million in 2022, and it would grow upto USD 1602.5 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Treatment-Resistant Depression Market Scope and Segmentation

Market Definition

Depression is a type of mental condition that is typically characterized by a continuous sense of sadness and a loss of interest. It affects how patients feel, think, and behave and can cause a variety of mental and physical difficulties. Antidepressants, which are pharmaceuticals that can help decrease symptoms of social anxiety disorder, depression, anxiety disorders, and seasonal affective disorder, are among the treatments available for treating depression. Patients who are suffering from depression and who have failed at least two trials of antidepressant medication which includes SSRI and SSNRI are, usually comprise the population known as treatment-resistant depression. 

Treatment-Resistant Depression Market Dynamics

Drivers

• Increased Research and Clinical Activities

Major market players in market are involved in gaining approvals for their novel treatment-resistant depression drugs and launching them readily in the market. Such approval and launch of novel drugs are specifically indicated for treatment-resistant depression and is anticipated to boost the market growth over the forecast period. For instance, Denovo Biopharma LLC, a clinical-stage biopharmaceutical company primarily focused on developing biomarker-driven precision medicines, has announced that the U.S. Food and Drug Administration authorized the company's investigational new drug (IND) application of DB104 (liafensine) in January 2022. It is used for treatment-resistant depression (TRD) to proceed, which allows Denovo to start a global Phase 2b clinical trial to evaluate the safety and efficacy of liafensine in patients.  

• Increasing Incidence of Depression

Growing incidence of depression is anticipated to boost the growth of the treatment-resistant depression market during the forecast period. For instance, as per the data published by National Institute of Mental Health in January 2022, an estimated 21.0 million adults in the U.S. suffer from at least one major depressive episode in 2020. This number represented 8.4% of all the U.S. adults in 2020. Thus, this boost the prevalence of treatment-resistant depression.

Opportunities

• Increased Prevalence of Product Launches

Growing development of novel therapeutics used for the treatment of resistant depression by market players to launch their novel products is anticipated to boost the market growth during the forecast period. For instance, XWPharma Ltd. announced dosing of subjects in its first-in-human study evaluating XW10508 in September 2021. It is the company’s novel, patented, glutamatergic NMDA antagonist and AMPA activator in development as an oral, once-daily therapy used to treat treatment-resistant depression and chronic pain. Thus, this factor significantly increases the market growth.

• Growing Funding from Several Government Organizations

Growing inorganic activities such as fundraising by different organizations to enlarge their presence in the market is projected to drive the market growth during the forecast period. For instance, Minded, the specialist in prescribing mental health medication online, announced US$ 25 million in seed funding in February 2022. Investors included Link Ventures, The Tiger Fund, Streamlined Ventures, Unicorn Ventures, Gaingels, SALT Fund, Trousdale Ventures, TheFund, and the founders of Care.com, Bolt, Gravity Blanket, RXBAR, and Gilt.com, combined with venture debt from Western Technology Investment (WTI). Thus, this increasing expenditure will increase the growth rate.

 Restraints/Challenges

• High Cost of Treatment

High cost of drugs which are used as treatment-resistant depression medication is anticipated to hinder the market growth over the forecast period 2023-2030. For instance, Johnson & Johnson announced that its nasal spray depression treatment, termed as Spravato, in March 2019, and global price will be at USD 590 for a 56 mg dose and US$ 885 for 84 mg. This increasing price rate will obstruct the market growth.

• Adverse Effects of Drug Reactions

Adverse drug reactions related with treatment-resistant depression medication is anticipated to limit the market growth during the forecast period. The most commonly witnessed adverse reactions in patients treated with SPRAVATO plus oral antidepressant (AD) were dissociation, nausea, sedation, dizziness, vertigo, anxiety, lethargy, hypoesthesia, blood pressure increase, intoxication, vomiting, and others. Thus, all these effects impede the market growth.

This treatment-resistant depression market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the treatment-resistant depression market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2022, COMPASS Pathways revealed positive data for Phase IIb study of COMP360 psilocybin therapy. This therapy is suitable for treatment-resistant depression treatment at the American Psychiatric Association annual meeting in New Orleans.
• In 2022, Denova Biopharma secured U.S. FDA approval to initiate a Phase 2b clinical trial to evaluate the efficacy and safety of DB104 (liafensine) in patients who said to be suffering from treatment-resistant mood disorder.

Global Treatment- Resistant Depression Market Scope

The treatment-resistant depression market is segmented on the basis of drug class, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Selective Serotonin Reuptake Inhibitors (SSRIS)
• Monoamine Oxidase Inhibitors
• Tricyclic Antidepressant
• Psychedelics
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Treatment- Resistant Depression Market Regional Analysis/Insights

The treatment-resistant depression market is analyzed and market size insights and trends are provided by drug class, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the treatment-resistant depression market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing a positive growth for treatment-resistant depression market throughout the forecast period because of the developing healthcare facilities, large number of generic manufacturer and increase in government initiatives and specialist communities. In addition to this, in recent years, there has been an increasing rate of adoption and growing demand for treatment resistant depression which is also anticipated to drive the regional market.

North America dominates the market due to the increased global leaders in research and development activities, fast approval process and rise in number of FDA approval drugs. Also, the high cases of mental illness is also boosting the growth of the market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Treatment- Resistant Depression Market Share Analysis

The treatment-resistant depression market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related treatment-resistant depression market.

Key players operating in the treatment-resistant depression market include:

• Pfizer Inc (U.S.)
• Mylan N.V. (U.S.)
• Novartis AG (Switzerland)
• Hikma Pharmaceuticals plc (U.K.)
• Aurobindo Pharma (India)
• AbbVie Inc. (U.S.)
• Melinta Therapeutics, Inc (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• GSK plc. (U.K.)
• Bayer AG (Germany)
• Lupin (India)
• Perrigo Company plc (U.S.)
• Johnson & Johnson Services, Inc (U.S.)
• Sun Pharmaceutical Industries Ltd.(India)
• Amneal Pharmaceuticals LLC. (U.S.)
• Aurobindo Pharma (India)
• Zydus Group (India)
• Teva Pharmaceutical Industries Ltd (Israel)
• Endo Pharmaceuticals plc (Ireland)
• Currax Pharmaceuticals LLC (U.S.)

SKU-53375